PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2018-05-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alzheimer's disease (AD) is the most common cause of dementia in elderly subjects. AD is characterized by brain lesions like extracellular deposits of ß-amyloïd proteins in senile plaques and intracellular neurofibrillary tangles of hyper-phosphorylated tau protein, both of which are associated with the loss of neurons. The development of disease biomarkers for AD (Tau, PhTau and βamyloid dosing in the cerebrospinal fluid, brain MRI, amyloid PET imaging and fluorodeoxyglucose PET imaging) to identify the pathophysiological processes underlying cognitive impairment biomarkers, have been incorporated into revised diagnosis guidelines.

Post-mortem human AD and AD animal model studies have reported inflammatory processes also implicated in the neuropathology of AD, and upregulated levels of pro-inflammatory cytokines.

In vivo visualization of microglial activation has become possible with the development of molecular imaging ligands (tracers) for use with positron emission tomography (PET). The translocator protein (TSPO) formerly known as the peripheral benzodiazepine receptor (PBR), a receptor located in the outer membrane of mitochondria, is upregulated during neuroinflammation. So targeting TSPO with radiolabeled ligands for PET is considered as an attractive biomarker for neuroinflammation.

The main aim of this pilot study is to quantify neuroinflammation, in terms of fixation and distribution of \[18F\] DPA-714(Binding Potential BP), and to study its relationship with amyloid load, measured with in \[18F\]AV-45 (Standard Uptake Values ratio) in cognitive decline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuroinflammation and Cognitive Decline in Alzheimer Disease

NCT02377206

Alzheimer Disease

COMPLETED EARLY_PHASE1

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

NCT05456503

Frontotemporal Lobar Degeneration Alzheimer Disease Cognitively Normal

RECRUITING PHASE3

FluoroAv45 Imaging Research-in Alzheimer's Disease

NCT01325259

Alzheimer's Disease Mild Cognitive Impairment

COMPLETED PHASE2

[18F]NIDF PET Imaging in Tau-related Diseases

NCT07306598

Neurodegenerative Disease Alzheimer s Disease Tauopathies

RECRUITING

Isotopic Imaging for Prodromal Alzheimer's Disease

NCT01231295

Alzheimer Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Molecular imaging of microglial activation could help us document the central inflammatory status of study subjects and assist us in designing future research studies particularly with respect to which subjects to enrol into clinical trials and to evaluate the benefit of specific therapies in selected groups, for example, by monitoring the effects of Aß immunization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Memory Complaint Mild Cognitive Impairment Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Memory complaint /MCI/ mild to moderate MA

Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients

Group Type EXPERIMENTAL

[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Criteria common to all participants:

* Signed informed consent
* Age ≥ 60 years old (60-80 years old)
* Native language: French
* Correct sensory abilities (hearing aids accepted) to perform the tests
* Affiliated to a social security system

Criteria for patients with mild to moderate Alzheimer disease defined according to the NINCDS-ADRDA {McKhann, 2011 # 408}:

* MMS between 20 and 25
* contraindication for MRI

Criteria for amnestic MCI patients:

* Amnestic mildcognitive disorder evoking a MA in pre stage dementia {Dubois, 2010 # 273, Dubois, 2007 # 42; Pertersen, 1999 # 21, Albert, 2011 # 409} older than 60 years.

Criteria for patients with isolated memory Complaint (Without Cognitive Decline):

* MMS score ≥ 26
* Normal performance by age and educational level

* medical history of evolutive disease with conséquences on NCS, chronic alcohol intake, severe depression with MADRS stage \> 18
* MA subjects : antagonistic treatment with N-methyl-D-aspartate
* MA or MCI subjects : anomaly on neurologic clinical examination different of the usual symptomatology

Minimum Eligible Age

60 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No